NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
6.18
-1.16 (-15.80%)
May 12, 2025, 3:41 PM - Market open
NTHI Revenue
NeOnc Technologies Holdings had revenue of $39.99K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $79.99K, up 13.52% year-over-year. In the year 2024, NeOnc Technologies Holdings had annual revenue of $83.00K with 17.79% growth.
Revenue (ttm)
$79.99K
Revenue Growth
+13.52%
P/S Ratio
1,666.25
Revenue / Employee
$9,999
Employees
8
Market Cap
115.85M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 83.00K | 12.54K | 17.79% |
Dec 31, 2023 | 70.46K | 50.46K | 252.31% |
Dec 31, 2022 | 20.00K | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNTHI News
- 27 days ago - NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets - GlobeNewsWire
- 4 weeks ago - NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September - GlobeNewsWire
- 4 weeks ago - NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President - GlobeNewsWire
- 4 weeks ago - NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy - GlobeNewsWire
- 6 weeks ago - NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas - GlobeNewsWire
- 6 weeks ago - NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments - GlobeNewsWire
- 6 weeks ago - NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors - GlobeNewsWire
- 6 weeks ago - NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors - GlobeNewsWire